• Lexicon outlined plans to present new clinical data on sotagliflozin in Type 1 diabetes, ahead of a targeted mid-2026 NDA resubmission.
• The results will be presented at the ADA 2026 Scientific Sessions on June 7, 2026 in New Orleans.
• The sotagliflozin analysis points to consistent blood-sugar improvement across patient subgroups, supporting the drug’s mechanistic profile in Type 1 diabetes.
• Separate ADA data on pilavapadin indicate kidney function did not meaningfully change the drug’s exposure, supporting broad use in diabetic nerve pain studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030800PRIMZONEFULLFEED9730782) on June 03, 2026, and is solely responsible for the information contained therein.